167 related articles for article (PubMed ID: 27114914)
1. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.
Shapiro EG; Rudser K; Ahmed A; Steiner RD; Delaney KA; Yund B; King K; Kunin-Batson A; Eisengart J; Whitley CB
Mol Genet Metab Rep; 2016 Jun; 7():32-9. PubMed ID: 27114914
[TBL] [Abstract][Full Text] [Related]
2. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB
Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037
[TBL] [Abstract][Full Text] [Related]
3. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.
Yund B; Rudser K; Ahmed A; Kovac V; Nestrasil I; Raiman J; Mamak E; Harmatz P; Steiner R; Lau H; Vekaria P; Wozniak JR; Lim KO; Delaney K; Whitley C; Shapiro EG
Mol Genet Metab; 2015 Feb; 114(2):170-7. PubMed ID: 25541100
[TBL] [Abstract][Full Text] [Related]
4. Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI.
Ahmed A; Shapiro E; Rudser K; Kunin-Batson A; King K; Whitley CB
Mol Genet Metab Rep; 2016 Jun; 7():27-31. PubMed ID: 27114913
[TBL] [Abstract][Full Text] [Related]
5. The natural history of neurocognition in MPS disorders: A review.
Shapiro EG; Eisengart JB
Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
[TBL] [Abstract][Full Text] [Related]
6. Mucopolysaccharidosis (MPS) Physical Symptom Score: Development, Reliability, and Validity.
Ahmed A; Rudser K; Kunin-Batson A; Delaney K; Whitley C; Shapiro E
JIMD Rep; 2016; 26():61-8. PubMed ID: 26303610
[TBL] [Abstract][Full Text] [Related]
7. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
9. Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion.
Guffon N; Journeau P; Brassier A; Leger J; Chevallier B
Eur J Pediatr; 2019 Apr; 178(4):593-603. PubMed ID: 30740618
[TBL] [Abstract][Full Text] [Related]
10. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
11. Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair.
Grant N; Sohn YB; Ellinwood NM; Okenfuss E; Mendelsohn BA; Lynch LE; Braunlin EA; Harmatz PR; Eisengart JB
Mol Genet Metab Rep; 2022 Mar; 30():100845. PubMed ID: 35242576
[TBL] [Abstract][Full Text] [Related]
12. [Link between depression and academic self-esteem in gifted children].
Bénony H; Van Der Elst D; Chahraoui K; Bénony C; Marnier JP
Encephale; 2007; 33(1):11-20. PubMed ID: 17457290
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Family pediatrics: report of the Task Force on the Family.
Schor EL;
Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
[TBL] [Abstract][Full Text] [Related]
15. Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights.
Martins AM; Lindstrom K; Kyosen SO; Munoz-Rojas MV; Thibault N; Polgreen LE
BMC Endocr Disord; 2018 Nov; 18(1):83. PubMed ID: 30419879
[TBL] [Abstract][Full Text] [Related]
16. Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children.
Soni-Jaiswal A; Mercer J; Jones SA; Bruce IA; Callery P
Orphanet J Rare Dis; 2016 Jul; 11(1):96. PubMed ID: 27406185
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
18. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
19. The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study.
Shapiro E; King K; Ahmed A; Rudser K; Rumsey R; Yund B; Delaney K; Nestrasil I; Whitley C; Potegal M
Mol Genet Metab Rep; 2016 Mar; 6():41-47. PubMed ID: 26918231
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
